Dr. Joe Jukic: Robert, I’ve been following this closely. In Japan, at Keio University, a team led by Hideyuki Okano and Masaya Nakamura took four people with complete spinal cord injuries—ASIA grade A, zero movement or sensation below the injury—and injected about two million neural progenitor cells made from iPS cells into the injury site. These were donor-derived, reprogrammed adult cells turned back into a stem-like state, then guided toward becoming neural precursors. The patients were treated in the subacute window, roughly two to four weeks after injury, and they got intensive rehab afterward.
Robert: And one of them actually stood up?
Dr. Jukic: Yes. After a year, one man went from complete paralysis to ASIA grade D. He can stand independently and has started practicing walking. Another improved to grade C—he can move some limbs, feed himself, push a wheelchair better. The other two didn’t show major grade changes, but the group as a whole had motor score gains that looked better than the usual spontaneous recovery rates. Crucially, no serious side effects, no tumors from the cells, and longer follow-up out to two–four years still looks clean on safety.
Robert: That’s… that’s the kind of result that makes you sit up in bed at night. So what the hell is stopping Canada from doing the same thing?
Dr. Jukic: Fair question. A few real barriers. Japan deliberately built a faster regulatory path for regenerative medicine. They can grant conditional, time-limited approval based mainly on safety and early signals of benefit, then collect the harder efficacy data while patients are already receiving the therapy. Canada, through Health Canada, still runs closer to the classic multi-phase trial model—safety first, then larger controlled efficacy studies, then approval. That protects against false hope and safety disasters, but it also means a promising early result like Keio’s stays in the research lane much longer.
Robert: So we’re safer on paper, but slower for people like me?
Dr. Jukic: That’s the trade-off. There’s also the practical side: manufacturing clinical-grade iPS-derived cells at scale under strict Good Manufacturing Practice standards is expensive and specialized. Japan already has a national iPS cell bank and experienced centers. Canada has excellent stem-cell scientists and some strong labs, but the infrastructure and sustained public-private funding to run even a modest four-to-ten patient first-in-human spinal cord study with the same cell product aren’t lined up the same way yet. Liability culture, insurance, hospital ethics boards, and the sheer cost of long-term follow-up all add friction.
Robert: Could we just import the Japanese protocol or collaborate?
Dr. Jukic: In theory, yes—scientific collaboration is open. But regulators still want Canadian data or at least a carefully justified bridging strategy. And for a condition as irreversible as complete spinal cord injury, ethics committees are understandably cautious about offering experimental cell transplants outside tightly controlled trials. The Japanese team themselves are careful: they call this a first safety study with encouraging signals, not a proven cure. Larger trials are still needed.
Robert: So while they move from four patients toward bigger studies, I sit here waiting for the Canadian system to catch up.
Dr. Jukic: I know. That’s the hard part of evidence-based medicine when the disease is this devastating. The honest answer is that Canada prioritizes rigorous proof of both safety and consistent benefit before wide access. Japan is willing to move faster on safety-plus-early-signal and then refine. Both approaches have logic. What’s encouraging is that the Japanese long-term safety data are now public, the motor gains exceeded historical controls, and the field is watching closely. If Canadian researchers can secure funding and regulatory clearance for a similar or confirmatory study, the path is clearer than it was five years ago.
Robert: Keep me posted, Doc. If there’s any legitimate trial doorway opening here, I want to know the second it appears.
Dr. Jukic: You will. And in the meantime we keep optimizing everything we can control—rehab intensity, spasticity, bone health, autonomic function, mindset. The Japanese result shows the biology can respond. Now the systems have to catch up.